Proteinuric Kidney Disease study: MZE829
Official title A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
ClinicalTrials.gov ID: NCT06830629
What this study is testing
What is MZE829?
MZE829 is an investigational oral capsule being studied for proteinuric kidney disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to evaluate how safe and well tolerated MZE829 is, and whether it lowers albuminuria (protein in urine) in adults with APOL1 kidney disease.
- Who it's for
- Adults who have APOL1 kidney disease.
- What's involved
- Participants will receive the drug MZE829 and attend scheduled visits for medical assessments and urine tests.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 68
You may be able to join if
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
- Chronic kidney disease with persistent albuminuria Key
You likely can't join if
- Organ or bone marrow transplantation
- History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
- Conditions that may alter drug absorption, e.g., history of bariatric surgery
- Type I diabetes
- Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Decatur, Alabama, United States
- Huntsville, Alabama, United States
- Montgomery, Alabama, United States
- Bloomfield, Connecticut, United States
- Washington D.C., District of Columbia, United States
- Atlantis, Florida, United States
- Brandon, Florida, United States
- Hollywood, Florida, United States
- Melbourne, Florida, United States
- Orlando, Florida, United States
- Atlanta, Georgia, United States
- College Park, Georgia, United States
- Cordele, Georgia, United States
- Macon, Georgia, United States
- Riverdale, Georgia, United States
- Savannah, Georgia, United States
- Snellville, Georgia, United States
- Chicago, Illinois, United States
- Evanston, Illinois, United States
- Kansas City, Kansas, United States
+ 46 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 68 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Decatur, Alabama, United States; Huntsville, Alabama, United States; Montgomery, Alabama, United States; Bloomfield, Connecticut, United States; Washington D.C., District of Columbia, United States; Atlantis, Florida, United States and 60 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.